Solti Group
Solti Group is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Sponsor Puma Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Solti Group?
The 2026-10-09 snapshot links Solti Group to 5 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, CSA negotiation, Document Handling/Filing, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Solti Group?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Solti Group conducted?
The linked trials record locations in 20 countries, including Spain, Belgium, Germany, Italy, Portugal. These are trial locations, not confirmed office locations or countries where Solti Group delivered services.
What can this page tell me about Solti Group's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Solti Group. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Solti Group